SINGULAIR NEW USE
Since launched in 1998, Singulair has always been indicated for prophylaxis and chronic treatment of asthma in patients from 2 years and up. Now Merck Frosst announced Singulair is also indicated for the relief of symptoms of seasonal allergic rhinitis (hay fever) in patients 15 years and older. There are no noticeable side effects when used for hay fever but in asthma patients, there is a little over 1% incidence of abdominal pain and headache. Patients with mild to moderate hepatic insufficiency may produce a higher blood level and longer elimination of the drug. Elevations in serum transaminases have been observed but mostly transient although jaundice has been reported.